MINNEAPOLIS, March 3 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) announced today the presentation of the findings of three studies on its Urgent(R) PC Neuromodulation System, a proprietary, minimally invasive nerve stimulation device, designed for office-based treatment of overactive bladder (OAB) symptoms, at the Society of Urologic Nurses and Associates (SUNA) Annual Symposium in Tampa, Florida. These retrospective and observational studies examined the use of the Urgent PC to deliver percutaneous tibial nerve stimulation (PTNS) for the treatment of OAB symptoms of urinary urgency, urinary frequency, and urge incontinence.
"These studies found that the Urgent PC is a viable, well-tolerated, nondrug option for the delivery of PTNS for treatment of OAB symptoms. The studies also reported reductions in the frequency of unwanted voids and incontinence, as well as a high level of self-reported patient satisfaction," said Dave Kaysen, the President and Chief Executive Officer of Uroplasty, Inc. "We believe, from a practice perspective, that Urgent PC is an effective, easy-to-administer treatment easily incorporated into routine patient care in an office setting."
In an oral presentation, "Percutaneous Tibial Nerve Stimulation: Revival of an Old Technology for Treatment of Overactive Bladder," Leslie Wooldridge, MSN, RNCS, GNP.F, BCIA-PMBD, Director of the Bladder Control Clinic from Hackley Health at the Lakes Women's Center in Muskegon, Michigan, presented results of 24 patients, who completed the initial twelve, 30-minute weekly Urgent PC treatments. Of the 24 patients, 19 patients with successful results transitioned to maintenance therapy with longer intervals between treatments. Two did not find the Urgent PC effective enough to continue the treatments and three discontinued the treatment for reasons unrelated to the treatment itself. Patients found a reduction in the daily average number of day voids from 11.16 to 8, night voids from 2.46 to 1.09 and incontinence episodes from 3.78 to 0.75.
In a poster presentation, "Percutaneous Tibial Nerve Stimulation (PTNS)
Treatment for Overactive Bladder (OAB) Patients in a Community Based
Urology Practice," Lesbia Candelaria, RN from Winter Park Urology
Associates, Orlando, Florida, conducted a retrospective evaluation of
sixteen patients, who successfully completed twelve, 30-minute weekly
Urgent PC treatments. Ms. Candelaria collected data on demographics, night
voids and subjective patient satisfaction and improvement at the end of the
treatment schedule. Of the 16 patients who completed the treatments, 5 were
female and 11 were male. The data showed decreases in the average night
voids and a high rate of patient satisfaction with the treatment. The
response to the survey questions indicated that after 12 treatments:
-- Greater than 50% of the patients improved night voids from a baseline
average of 3.6 to an average of 1.8.
-- Greater than 80% of patients were totally or highly satisfied with the
Urgent PC treatments.
-- Approximately 72% of patients rated themselves as highly or totally
-- 100% of the patients who answered this question (n=8) said they would
definitely or likely recommend Urgent PC treatments to a friend with
In another poster presentation, "Percutaneous Tibial Nerve Stimulator: A Viable Option for Urgency, Frequency, and Urge Incontinence," Vanessa K. Hardy, WHNP, APN, MSN, a urogynecology nurse practitioner from Vanderbilt University Medical Center in Nashville, Tennessee, conducted a retrospective review of 12 Urgent PC patients. Ms. Hardy collected data on primary diagnosis, duration of treatment, and changes in urinary frequency, urgency, and urge incontinence. Following the twelve, 30-minute weekly Urgent PC treatments, 30% of the patients (or 4 patients) reported at least 50% or more improvement in their symptoms.
About the Urgent PC Neuromodulation System
The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of OAB symptoms of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms of OAB. Uroplasty sells the Urgent PC system in the United States, Canada and countries recognizing the CE mark. Outside of the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with
wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a
medical device company that develops, manufactures and markets innovative
proprietary products for the treatment of voiding dysfunctions. Our primary
focus is the commercialization of our Urgent PC system, which we believe is
the only FDA- approved non-surgical neurostimulation therapy for the
treatment of overactive bladder (OAB) symptoms. We also offer
Macroplastique(R) Implants, a bulking agent for the treatment of urinary
incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, and Treasurer,
Julie Huang/Matt Selinger (Investors)
Steve DiMattia/Chris Gale (Media)
|SOURCE Uroplasty, Inc.|
Copyright©2008 PR Newswire.
All rights reserved